White Drug 63 Medicare Supplier Location: 425 College Dr S Ste 10, Devils Lake, North Dakota 58301 Phone: (701) 662-6270 |
Dl Clinic Pharmacy Inc Community/Retail Pharmacy Location: 1001 7th St Ne, Devils Lake, North Dakota 58301 Phone: (701) 662-4427 |
Ramsey Drug Community/Retail Pharmacy Location: 401 College Drive So, Devils Lake, North Dakota 58301 Phone: (701) 662-3117 |
Yorhom Medical Essentials DME Supplier - Oxygen Equipment & Supplies Location: 210 Highway 2 W, Devils Lake, North Dakota 58301 Phone: (701) 544-2100 |
White Drug #47 Dba Bell Drug Durable Medical Equipment & Medical Supplies Location: 323 5th St Ne, Devils Lake, North Dakota 58301 Phone: (701) 662-3022 |
Krein And Moen, Pc Medicare Supplier Location: 404 Highway 2 E, Devils Lake, North Dakota 58301 Phone: (701) 662-4085 |
Krein And Moen Pc Medicare Supplier Location: 211 4th Nest 1, Devils Lake, North Dakota 58301 Phone: (701) 662-2040 |
News Archive
Children with an extremely deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found exclusively on cancer cells, according to a new study led by UC San Francisco researchers.
New therapies for some forms of epilepsy may soon be possible, thanks to a discovery made by a team of University of British Columbia and Vancouver Coastal Health Research Institute neuroscience researchers.
Moles are benign tumors found on the skin of almost every adult. Scientists have known for years that a mutation in the BRAF gene makes them start growing, but until now haven't understood why they stop. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that keeps moles in their usual non-cancerous, no-growth state.
In response to concerns from hospitals to prepare for eventual pandemic flu outbreaks, the French company AirInSpace, with support from ESA's Technology Transfer Programme, has successfully adapted technology developed to protect astronauts for use in critical care centres to protect immune-deficient patients against airborne pathogens such as the avian flu virus.
After a lightening round of proposals and reviews, an international team of scientists led by Dr. Camillo Ricordi was granted immediate FDA authorization for a 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells to block the life-threatening lung inflammation that accompanies severe cases of COVID-19.
› Verified 8 days ago